









Markets
/
Stocks
/
nasdaq-bway
/

Brainsway Ltd

BWAY



View Detailed Chart

19.370USD

+0.080+0.41%

Close 12/26, 16:00（ET）Quotes delayed by 15 min

368.10MMarket Cap

58.76P/E TTM



Brainsway Ltd

19.370

+0.080+0.41%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+0.41%

5 Days

+13.21%

1 Month

+22.36%

6 Months

+46.52%

Year to Date

+105.41%

1 Year

+112.16%

View Detailed Chart

TradingKey Stock Score of Brainsway Ltd

Currency: USD Updated: 2025-12-26

Key Insights

Brainsway Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 63/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Brainsway Ltd's Score

Industry at a Glance

Industry Ranking

63 / 207

Overall Ranking

174 / 4563

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

23.500

Target Price

+32.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Brainsway Ltd Highlights

StrengthsRisks

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 50.92% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 41.02M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 58.76, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 6.12M shares, increasing 8.58% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 313.16K shares of this stock.